Physician profile
Fernando Raudales
NPI 1801880307
$30,200.77
in general payments reported to CMS, 2019-2025
44 companies · $3,244 in 2025
The $3,244 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,493 · 2020: $750 · 2021: $2,360 · 2022: $2,488 · 2023: $16K · 2024: $2,681 · 2025: $3,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $11K · Food and Beverage: $8,988 · Travel and Lodging: $1,740 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $11,000.00 |
| Food and Beverage | $8,988.19 |
| Travel and Lodging | $1,739.66 |
| Education | $382.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $13,992.27 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $2,285.37 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,849.02 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Vifor Pharma, INC. | $1,146.06 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $971.55 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $844.45 | 2021-2025 | |
| Horizon Therapeutics Plc | $787.93 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $783.58 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $733.26 | 2019-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $669.27 | 2019-2025 | Rayaldee |
| Ardelyx, INC. | $574.11 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Mallinckrodt Hospital Products INC. | $559.73 | 2021-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $545.23 | 2022-2025 | Filspari |
| Glaxosmithkline, LLC. | $461.95 | 2021-2025 | Benlysta |
| Veloxis Pharmaceuticals, INC. | $434.78 | 2019-2023 | Envarsus |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $415.59 | 2019-2023 | Ultomiris |
| Fresenius USA Marketing, INC. | $284.57 | 2019-2024 | Velphoro |
| Merck Sharp & Dohme LLC | $281.23 | 2023-2025 | Prevymis, Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.18 | 2020-2025 | Jardiance |
| Genzyme Corporation | $263.23 | 2019-2023 | |
| Nxstage Medical, INC. | $237.31 | 2021-2023 | Nxstage System One |
| Takeda Pharmaceuticals U.S.A., INC. | $230.96 | 2021-2025 | Livtencity |
| Novartis Pharmaceuticals Corporation | $189.43 | 2021-2025 | |
| Novo Nordisk INC | $171.55 | 2020-2025 | Ozempic, Wegovy |
| Medtronic, INC. | $160.18 | 2025 | Ellipsys Vascular Access System |
| Mallinckrodt Enterprises LLC | $110.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $108.40 | 2019-2020 | |
| Amarin Pharma, INC. | $108.37 | 2019 | |
| Lilly USA, LLC | $102.02 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $97.75 | 2023-2024 | Gvoke Hypopen |
| Pfizer INC. | $87.64 | 2019-2022 | |
| Scpharmaceuticals INC. | $61.85 | 2025 | |
| Ani Pharmaceuticals, INC. | $61.34 | 2022-2025 | Purified Cortrophin Gel |
| Cardiovascular Systems INC. | $50.71 | 2021 | |
| Cormedix INC. | $49.02 | 2024 | Defencath |
| Dexcom, INC. | $42.70 | 2023-2024 | Dexcom G6 Transmitter |
| Apellis Pharmaceuticals, INC. | $32.82 | 2025 | |
| Ascendis Pharma Endocrinology INC | $28.51 | 2025 | Yorvipath |
| Daiichi Sankyo INC. | $24.53 | 2021 | |
| Alnylam Pharmaceuticals INC. | $23.47 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.66 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $14.86 | 2023 | Inpefa |
| Allergan, INC. | $14.70 | 2020 | |
| Strongbridge US INC. | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Raudales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.